John Johnston, Director at MaxCyte, Inc. (NASDAQ:MXCT), a $434 million market cap company, recently sold 3,000 shares of common stock, netting $12,020. The stock traded at a weighted average price of $4.007 per share, with individual transaction prices ranging from $3.995 to $4.06, near the bottom of the 52-week range of $3.17 to $5.54. These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Johnston on December 19, 2023.
In addition to the sale, Johnston exercised options to purchase 3,000 shares of MaxCyte common stock at a price of $2.932 per share. Following these transactions, Johnston directly holds 141,950 shares.
The exercise of the option and the subsequent sale were part of the planned transactions, as outlined in the trading plan, thereby ensuring transparency and compliance with SEC regulations.
In other recent news, MaxCyte, Inc. announced its financial results for the third quarter ended September 30, 2024. The earnings call, led by President and CEO Maher Masoud and CFO Doug Swirsky, provided insight into the company’s performance and future strategies. The management team expressed optimism about MaxCyte’s trajectory and future performance, despite acknowledging possible factors that could cause actual results to differ from projections. Forward-looking statements are made, emphasizing the inherent uncertainty of such predictions. During the call, they did not discuss specific financial failures. Executive discussions and a subsequent question-and-answer session offered stakeholders a clearer understanding of MaxCyte’s strategic direction and operational focus. These are among the recent developments at the company.
This article was generated with the support of artificial intelligence and reviewed by an editor. See our T&C for more information.
